References
- Audia JE, Campbell RM. 2016. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 8(4):a019521.
- Bell L, Bickford S, Nguyen PH, Wang J, He T, Zhang B, Friche Y, Zimmerlin A, Urban L, Bojanic D. 2008. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J Biomol Screen. 13(5):343–353.
- Cao Q, Wang X, Zhao M, Yang R, Rohit MR, Qiao Y, Anton PA, Anastasia K, Yocum AK, Li Y, et al. 2014. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 5:3127–3140.
- Gad SC. 2008. Preclinical development handbook: ADME and biopharmaceutical properties. Hoboken (NJ): John Wiley & Sons; p. 1117–1119.
- Huang Y, Zhang J, Yu Z, Zhang H, Wang Y, Lingel A, Qi W, Gu J, Zhao K, Shultz MD, et al. 2017. Discovery of first-in-class, potent and orally bioavailable EED inhibitor with robust anti-cancer efficacy. J Med Chem. 60(6):2215–2226.
- Huang Y, Zhang J, Sendzik M, Gao Z, Sun Y, Wang L, et al. 2021. Discovery of the clinical candidate MAK683: an EED-directed, allosteric and selective PRC2 inhibitor for the treatment of advanced malignancies. J Med Chem. Submitted.
- Jung JW, Choi MR, Kwon YS, Jeong JS, Son M, Kang HE. 2015. Gender differences in corydaline pharmacokinetics in rats. Xenobiotica. 45(5):456–463.
- Kato R, Yamazoe Y. 1992. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol Lett. 64–65:661–667.
- Kim KH, Roberts CWM. 2016. Targeting EZH2 in cancer. Nat Med. 22(2):128–134.
- Malatkova P, Maser E, Wsol V. 2010. Human carbonyl reductases. Curr Drug Metab. 11(8):639–658.
- Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ, Voigt P, Martin SR, Taylor WR, De Marco V, et al. 2009. Role of the polycomb protein EED in the propagation of repressive histone Marks. Nature. 461(7265):762–767.
- Margueron R, Reinberg D. 2011. The polycomb complex PRC2 and its mark in life. Nature. 469(7330):343–349.
- McCabe MT, Creasy CL. 2014. EZH2 as a potential target in cancer therapy. Epigenomics. 6(3):341–351.
- Payne AH, Hales DB. 2004. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 25 (6):947–970.
- Qi W, Zhao K, Gu J, Huang Y, Wang Y, Zhang H, Zhang M, Zhang J, Yu Z, Li L, et al. 2017. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol. 13(4):381–388.
- Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, et al. 2002. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419(6907):624–629.
- Varma MVS, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, Thomas NS, Pillai O, Sharma P, Gandhi R, Agrawal S, Nair V, Panchagnula R. 2004. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab. 5:375–388.
- Xu C, Bian C, Yang W, Galka M, Ouyang H, Chen C, Qiu W, Liu H, Jones AE, MacKenzie F, et al. 2010. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc Natl Acad Sci USA. 107(45):19266–19271.
- Yuan Y, Yang D, Zhang JY, Bible R, Karim A, Findlay JWA. 2002. Disposition of a specific Cox-2 inhibitor, Valdecoxib, in human. Drug Metab Dispos. 30(9):1013–1021.
- Zhang JY, Wang YF, Yang D, Dudkowski C, Chang M, Yuan Y, Paulson S, Breau A. 2000. Determination of metabolites of new ant-inflammatory drug Celecoxib in female rabbits by tandem mass spectrometry. J Mass Spectrom. 35(11):1259–1270.